• Zhen Xiang, Xin Lin, Jun Wang, and Guodan Yu.
• Department of Nephropathy Rheumatism, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, Hubei Province, China.
• Medicine (Baltimore). 2022 Oct 14; 101 (41): e30949.

BackgroundIntradialytic hypotension (IDH) is a common complication in hemodialysis. IDH can induce vomiting, chest tightness and syncope, and hemodialysis shall be discontinued in patients with severe IDH. As is revealed in related studies, Shenmai injection (SMI) can be used in the prophylaxis and treatment of IDH. However, there is still a lack of consensus about the efficacy among reported studies, which cannot provide compelling evidence. Therefore, a meta-analysis was conducted in this study to further investigate the efficacy and safety of SMI in the prophylaxis and treatment of IDH.MethodsPubMed, Web of Science, Scopus, Cochrane Library, Embase, China Scientific Journal Database, China National Knowledge Infrastructure, Chinese Biomedical Literature Database, and Wanfang Data were systematically retrieved from their establishment to June 2022. Subsequently, literature screening, data extraction, quality evaluation and cross-checking of results were performed according to the Cochrane Handbook. Besides, a meta-analysis was performed with the assistance of Revman 5.3 software.ResultsThis study will evaluate whether SMI is effective in the prophylaxis and treatment of IDH.ConclusionsThe latest evidence for the efficacy and safety of SMI in the prevention and treatment of IDH can be provided through this study.Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

12 keywords...

hide…